In the realm of drug discovery, protein degraders are emerging as a groundbreaking approach with the potential to combat previously deemed untreatable diseases. Diverging from traditional drugs that merely obstruct specific protein functions, degraders bring about a transformative shift in the cell's natural degradation process. This alteration enables the elimination of disease-associated proteins. Despite their promise, a lingering challenge remains — resistance. A recent breakthrough study led by Dr. Cristina Mayor-Ruiz and Dr. Antoni Riera at IRB Barcelona, published in Angewandte Chemie International Edition, advances our understanding of and provides strategies to counter resistance to these innovative drugs.
Confronting Resistance in Cancer Treatment
Resistance development poses a formidable obstacle in cancer treatment efficacy. The rapid reproduction of cancer cells allows them to adapt and develop resistance to drugs, diminishing the effectiveness of treatments over time. This challenge is particularly pronounced in protein degraders, which, while holding great promise, are susceptible to resistance.
The researchers took on this challenge by focusing on the cellular model exhibiting the highest resistance to protein degraders known to date. Their primary objective was to identify a drug capable of selectively targeting and eliminating these resilient cells.
After an exhaustive process of chemical screening and optimization, the team identified RBS-10, a drug with the ability to selectively remove resistant cells, offering a promising solution to this persistent issue.
NQO1: A Vulnerability in Resistant Cells
To unravel the mechanism behind RBS-10's effects, the researchers scrutinized its mode of action. Through chemoproteomics, they identified the enzyme NQO1 as the primary target of RBS-10. Intriguingly, the resistant cellular model exhibited a substantial increase in NQO1 expression. Further investigations using proteomics, metabolomics, and genetic approaches unveiled a pivotal detail: RBS-10 functions as a prodrug. Its activation occurs only after metabolic processing by NQO1 in resistant cells.
Dr. Mayor-Ruiz remarked, "We felt like 'molecular detectives' in this project, utilizing various chemical biology approaches to discover that RBS-10 operates as a prodrug. Our findings not only provide valuable molecular insights into RBS-10's mechanism but also hold potential implications for the development of future therapies."
As protein degraders advance toward clinical applications, comprehending resistance mechanisms becomes paramount. Dr. Riera concludes, "Importantly, drugs in pre-clinical and clinical stages that function similarly to RBS-10 may hold the key to addressing resistance to protein degraders in clinical settings."
Related Queries dna mitosis mitochondria meiosis homeostasis cellular respiration osmosis nucleus animal cell plant cell cell membrane chloroplast cytoplasm prophase carbohydrates transcription interphase nucleotide what does dna stand for diffusion metaphase ribosomes codon chart anaphase cytokinesis